

## PRODUCT SPECIFICATION

Product Name	Anti-PIK3CA
Product Number	AMAb91513
Clone Number	CL8345
Gene Description	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
Clonality	Monoclonal
Isotype	IgG1
Host	Mouse
Purification Method	Protein A purified
Verified Species Reactivity	Human
Recommended Applications	WB (Western Blot) - Working concentration: 1 µg/ml
Characterization Data	Available at <a href="https://atlasantibodies.com/products/AMAb91513">atlasantibodies.com/products/AMAb91513</a>
Buffer	The antibodies are delivered in 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
Concentration	Lot dependent
Storage	Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Notes	The antibody solution should be gently mixed before use. Optimal concentrations and conditions for each application should be determined by the user. For protocols, additional product information, such as images and references, see <a href="https://atlasantibodies.com">atlasantibodies.com</a> .

 *Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB.*

**Warranty:** The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions. Atlas Antibodies AB's sole liability is limited to replacement of the product or refund of the purchase price. All products are supplied for research use only. They are not intended for medicinal, diagnostic or therapeutic use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB Rev. December 2012